InvestorsHub Logo
Followers 101
Posts 13186
Boards Moderated 0
Alias Born 06/01/2013

Re: Work Harder post# 20175

Saturday, 09/12/2020 8:14:57 PM

Saturday, September 12, 2020 8:14:57 PM

Post# of 27659
Merck KGaA teams up to advance Baylor College's potential COVID-19 vaccines

Merck KGaA is extending its collaboration with Baylor College of Medicine to advance a manufacturing platform for the institute's potential vaccines against COVID-19.

The life science business of the German company, along with researchers at Baylor College and the Texas Children's Hospital Center for Vaccine Development will work to improve the manufacturing platform for CoV RBD219-N1, which is expected to enter clinical trials later this year. The potential vaccine was originally developed to target SARS.

The teams will also develop a new manufacturing platform for a second vaccine candidate to shorten the time to enter into phase 1 clinical trials.

Merck will help in large-scale manufacturing of the potential vaccines, the company said in a May 27 press release.

The company and the Texas Children's Center for Vaccine Development initially formed a partnership in 2018 to advance vaccine development and production to enhance the response to outbreaks.

Baylor College and Texas Children's Center for Vaccine Development are also collaborating with Swiss biotech Mymetics Corp. to create a potential COVID-19 vaccine.

As of May 28, there have been over 5.6 million confirmed cases of COVID-19 and more than 353,200 deaths due to the disease worldwide, according to Johns Hopkins University's Center for Systems Science and Engineering.

First time I've read them in the same article together yet it's still vague

Twas posted before ?

https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/merck-kgaa-teams-up-to-advance-baylor-college-s-potential-covid-19-vaccines-58809822

Principal company Partner company

Mymetics and Baylor College of Medicine to develop COVID-19 vaccines Baylor College of Medicine Mymetics Corp. Payment unspecified 5/18/20

European Vaccine Initiative to provide development services to Mymetics' CoV RBD219-N1 for COVID-19 infection European Vaccine Initiative Mymetics Corp. Payment unspecified 6/11/20

https://www.bioworld.com/biopharma-nonprofit-collaborations-2020
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMX News